Lixte Biotechnology Holdings Inc (LIXT)
2.64
-0.03
(-1.18%)
USD |
NASDAQ |
May 14, 16:00
2.64
0.00 (0.00%)
After-Hours: 20:00
Lixte Biotechnology Holdings Net Income (Quarterly): -1.032M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -1.032M |
| September 30, 2023 | -1.019M |
| June 30, 2023 | -1.668M |
| March 31, 2023 | -1.368M |
| December 31, 2022 | -1.631M |
| September 30, 2022 | -1.478M |
| June 30, 2022 | -1.546M |
| March 31, 2022 | -1.657M |
| December 31, 2021 | -2.029M |
| September 30, 2021 | -1.239M |
| June 30, 2021 | -1.733M |
| March 31, 2021 | -1.727M |
| December 31, 2020 | -0.9069M |
| September 30, 2020 | -1.602M |
| June 30, 2020 | -0.3731M |
| March 31, 2020 | -0.3832M |
| December 31, 2019 | -0.3221M |
| September 30, 2019 | -1.079M |
| June 30, 2019 | -0.6105M |
| March 31, 2019 | -0.4287M |
| December 31, 2018 | -0.3486M |
| September 30, 2018 | -1.034M |
| June 30, 2018 | -0.3714M |
| March 31, 2018 | -0.3792M |
| December 31, 2017 | -0.4326M |
| Date | Value |
|---|---|
| September 30, 2017 | -0.4624M |
| June 30, 2017 | -0.2928M |
| March 31, 2017 | -0.6206M |
| December 31, 2016 | -0.5163M |
| September 30, 2016 | -0.6469M |
| June 30, 2016 | -0.555M |
| March 31, 2016 | -0.4165M |
| December 31, 2015 | -0.6139M |
| September 30, 2015 | -0.7797M |
| June 30, 2015 | -0.5007M |
| March 31, 2015 | -0.9579M |
| December 31, 2014 | -0.5947M |
| September 30, 2014 | -0.5014M |
| June 30, 2014 | -0.7413M |
| March 31, 2014 | -0.9288M |
| December 31, 2013 | -0.359M |
| September 30, 2013 | -0.3131M |
| June 30, 2013 | -0.3688M |
| March 31, 2013 | -0.3339M |
| December 31, 2012 | -0.2757M |
| September 30, 2012 | -1.978M |
| June 30, 2012 | -0.734M |
| March 31, 2012 | -0.5919M |
| December 31, 2011 | -0.6701M |
| September 30, 2011 | -0.6991M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-2.029M
Minimum
Dec 2021
-0.3221M
Maximum
Dec 2019
-1.232M
Average
-1.368M
Median
Mar 2023
Net Income (Quarterly) Benchmarks
| iBio Inc | -8.211M |
| PAVmed Inc | -14.04M |
| PDS Biotechnology Corp | -10.90M |
| Moleculin Biotech Inc | -4.97M |
| Syros Pharmaceuticals Inc | -64.38M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.026M |
| EPS Diluted (Quarterly) | -0.41 |
| Enterprise Value | 5.235M |
| Earnings Yield | -102.3% |